Claims
- 1. A method for treatment of tumors comprising administering to a patient diagnosed as having a tumor therapeutically effective amounts of 10-propargyl-10-deazaaminopterin and a taxane, wherein the tumors are selected from the group consisting of mammary tumors, lung cancer, prostate cancer and leukemias.
- 2. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.
- 3. The method of claim 1, wherein the tumor is a solid tumor.
- 4. The method of claim 3, wherein the tumor is a mammary tumor.
- 5. The method of claim 3, wherein the tumor is a lung tumor.
- 6. The method of claim 3, wherein the tumor is a prostate tumor.
- 7. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly.
- 8. The method of claim 1, wherein the taxane is administered immediately following the 10-propargyl-10-deazaaminopterin.
- 9. The method of claim 8, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.
- 10. The method of claim 8, wherein the tumor is a solid tumor.
- 11. The method of claim 10, wherein the tumor is a mammary tumor.
- 12. The method of claim 10, wherein the tumor is a lung tumor.
- 13. The method of claim 10, wherein the tumor is a prostate tumor.
- 14. The method of claim 8, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly.
- 15. A method for treatment of tumors comprising administering to a human patient diagnosed as having a tumor a therapeutically effective amount of 10-propargyl-10-deazaaminopterin, wherein the 10-propargyl-10-deazaaminopterin is administered in biweekly doses, and wherein the tumor is selected from the group consisting of mammary tumors, lung cancer, prostate cancer and leukemias.
- 16. The method of claim 15, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of 150 mg/m2/biweekly dose.
- 17. The method of claim 15, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.
- 18. A method for treatment of tumors comprising administering to a patient diagnosed as having a tumor therapeutically effective amounts of 10-propargyl-10-deazaaminopterin and a taxane, wherein the tumors are selected from among tumors expressing folyl polyglutamate synthetase and wherein the folyl polyglutamate synthetase is effective to catalyze the polyglutamylation of the 10-propargyl-10-deazaaminopterin.
Parent Case Info
This application is a continuation-in-part of U.S. patent application Ser. No. 09/214,984 , filed Mar. 8, 1999, now U.S. Pat. No. 6,028,091 which is incorporated herein by reference and claims benefit of U.S. Provisional Application No. 60/021,908 filed Jul. 7, 1996 and also a 371 of PCT/V597/11982 filed Jul. 16, 1997.
US Referenced Citations (4)
Non-Patent Literature Citations (2)
Entry |
Starling, et al., Cancer Chemotherapy Reports, Part 1, col. 58, No. 5, Sep./Oct. 1974. |
J. I. DeGraw, W.T. Colwell, JR. Piper, F.M. Sirotnak, “Synthesis and Antiumor Activity of 10-Propargyl-10-deazaaminopterin”, J. Med. Chem., 1993, vol. 36, pp. 2228-2231. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/021908 |
Jul 1996 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US97/11982 |
Jul 1997 |
US |
Child |
09/214984 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/214984 |
Mar 1999 |
US |
Child |
09/505571 |
|
US |